Skaarud Kristin J, Hjermstad Marianne J, Bye Asta, Veierød Marit B, Gudmundstuen Anne M, Lundin Knut E A, Distante Sonia, Brinch Lorentz, Tjønnfjord Geir E, Iversen Per O
Department of Haematology, Oslo University Hospital, Norway; Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Norway.
European Palliative Care Research Centre, Department of Oncology, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Clin Nutr ESPEN. 2018 Dec;28:59-66. doi: 10.1016/j.clnesp.2018.08.002. Epub 2018 Aug 29.
BACKGROUND & AIMS: Reduced quality of life (QoL) is prevalent after allogeneic hematopoietic stem cell transplantation (allo-HSCT). In this randomized trial we examined the effect of individualized nutritional support during hospitalization for allo-HSCT. Primary outcome was change in global QoL three months post-HSCT with oral mucositis (OM) and acute graft-versus-host disease (aGVHD) as main secondary outcomes.
Whereas the intervention group received recommended minimum daily intakes of 126 kJ/kg and 1.5-2.0 g protein/kg as food, supplements, enteral or parenteral nutrition, the controls received routine feeding. QoL was self-reported using the EORTC QLQ-C30 questionnaire.
Between August, 2010 and February, 2016, we randomized 59 and 60 patients to intervention and control, respectively; 40 and 48 being eligible for analysis of QoL. There was no difference between the two groups in mean global QoL after three months (-3.10, 95% CI -11.90-5.69; P = 0.49). Nor were there any differences in OM grades 3 or 4 (RR (vs grades 0-2), 1.11, 95% CI 0.59-2.11 and 0.95, 95% CI 0.72-1.25, respectively; P = 0.78), or aGVHD grades 3 or 4 (RR (vs grades 0-2) 0.44, 95% CI 0.12-1.60; and 0.65, 95% CI 0.20-2.20, respectively; P = 0.37).
Individualized nutritional support with recommended energy and protein intakes during hospitalization had no effect on QoL, OM or aGVHD three months after allo-HSCT compared to routine nutrition.
异基因造血干细胞移植(allo-HSCT)后生活质量(QoL)下降很常见。在这项随机试验中,我们研究了allo-HSCT住院期间个体化营养支持的效果。主要结局是HSCT后三个月全球QoL的变化,主要次要结局为口腔黏膜炎(OM)和急性移植物抗宿主病(aGVHD)。
干预组接受推荐的每日最低摄入量,即126kJ/kg和1.5 - 2.0g蛋白质/kg,通过食物、补充剂、肠内或肠外营养提供;对照组接受常规喂养。使用欧洲癌症研究与治疗组织(EORTC)QLQ-C30问卷自我报告QoL。
在2010年8月至2016年2月期间,我们分别将59例和60例患者随机分配至干预组和对照组;40例和48例符合QoL分析条件。三个月后,两组的平均全球QoL无差异(-3.10,95%CI -11.90 - 5.69;P = 0.49)。3级或4级OM也无差异(RR(与0 - 2级相比)分别为1.11,95%CI 0.59 - 2.11和0.95,95%CI 0.72 - 1.25;P = 0.78),3级或4级aGVHD也无差异(RR(与0 - 2级相比)分别为0.44,95%CI 0.12 - 1.60;和0.65,95%CI 0.20 - 2.20;P = 0.37)。
与常规营养相比,allo-HSCT后三个月住院期间给予推荐能量和蛋白质摄入量的个体化营养支持对QoL、OM或aGVHD没有影响。